Study Evaluating AGG-523 in Subjects With Osteoarthritis

This study has been completed.
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer Identifier:
First received: January 25, 2007
Last updated: August 1, 2008
Last verified: August 2008
This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.

Condition Intervention Phase
Drug: AGG-523
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel-Group Study of the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of AGG-523 Administered Orally to Subjects With Mild to Moderate Osteoarthritis

Resource links provided by NLM:

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • The effect of AGG-523 on biomarkers related to osteoarthritis.

Study Start Date: February 2007
Study Completion Date: June 2007

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Mild to moderate Osteoarthritis of the target knee.
  • Subjects must be generally healthy but enrolled with stable chronic illness if well controlled.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00427687

United States, California
Anaheim, California, United States, 92801
United States, Florida
Miami, Florida, United States, 33143
United States, Pennsylvania
Altoona, Pennsylvania, United States, 16635
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information Identifier: NCT00427687     History of Changes
Other Study ID Numbers: 3189A1-104 
Study First Received: January 25, 2007
Last Updated: August 1, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases processed this record on May 22, 2016